Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 1, 2010
Thu, September 30, 2010
NORTH BRUNSWICK, N.J.--([ BUSINESS WIRE ])--[ Advaxis, Inc ]., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, conducted a shareholder conference call Tuesday, September 28, 2010 at 12:30 pm.
"We can say that the recent volatility is clearly creating a dislocation in the market which really isna™t tied to the reality of the companya™s situation."
Following is a recap of the points discussed, statements made or investor questions asked:
- aWe can say that the recent volatility is clearly creating a dislocation in the market which really isna™t tied to the reality of the companya™s situation.a
- aYour Management strongly believes that the true value of the Company is in its novel science which continues to increase with every new patent, every new construct, every new trial and every new strategic collaboration.a
a"Thomas A. Moore, Chairman/CEO
- aWe completed a portion of our overall financing agreement with Optimus Life Science Capital Partners for $1.51 million earlier today. We are executing this with the sale of shares to Optimus, as is more fully described in an 8K that will be filed today and our recent 10Q that was filed in mid September this year.a
- aWe believe the exercise of the warrants from our mid August 2010 transaction and perhaps the exercise of warrants over the last few weeks was a key factor in the recent trading activity of Advaxis stock.a
a"Mark Rosenblum, CFO
- aAll of our clinical trials are progressing as we hoped they would.a
- aThe trial in CIN, cervical intraepithelial neoplasia, has passed the vanguard phasea We expect to get through our DSMB Meeting [safety meeting] in the early part of the next year and continue on track and on schedule with this trial.a
- aThe India study has been approved by the Indian government. All of the details have been arrangeda As a condition of approval, the approval agency wanted to assay our drug and make sure that the drug we provided adhered to the specification we gave them. They are assaying our drug now and we expect that will be done in the next week or two and we will begin enrolling patients in the India trial.a
- aOur collaboration with the gynecologic oncology group or G.O.G. is on track. We have passed some major committee meeting hurdles at N.C.I. and have only one more submission to make to the R.A.C., the Recombinant Advisory Board, with the protocol that G.O.G. has had approved; and once thata™s done, we can begin to enroll patients in that trial.a
- aIn the U.K., that trial is scheduled to begin either by the end of this year or perhaps early in next year depending on how quickly we can import the drug back into Englanda The agreements have been signed, the funding has been obtained, the centers are online, and as soon as we can get regulatory permission to ship the drug, we will and that study will commence.a
- aIn the animal arena we have a veterinary trial that we have signed an agreement with the vet school at the University of Pennsylvania to conduct, that study drug has been made and again we are waiting for regulatory approval from the U.S.D.A. to begin that trial.a
a"Dr. John Rothman, EVP of Science & Operations
For further information, readers are encouraged to refer to Advaxisa™ most recent Form 10-Q filed on September 14, 2010 and Form 8-K regarding the latest funding. This SEC filing and all company filing can be viewed and/or downloaded from the U.S. Securities and Exchange Commissiona™s website ([ www.sec.gov ]).
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeriamonocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the [ City of Hope ], the [ Roswell Park Cancer Institute ], the [ National Cancer Institute ], the [ University of Pittsburgh ], [ Cancer Research a" UK ] and the [ U.S. Department of Homeland Security ]. Advaxisa™ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisa™ scientific advisory board.
Please visit the Companya™s portals: [ advaxis.com ] | [ facebook ] | [ twitter ] | [ LinkedIn ]
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.Forward-looking statements deal with the Companya™s current plans, intentions, beliefs and expectations and statements of future economic performance.Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated.Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.The Company cannot guarantee its future results, levels of activity, performance or achievements.
